OrbiMed’s Allakos ALLK Stock Holding History

OrbiMed’s Portfolio ALLK Stock Details ALLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-175,000	Closed	-$9.15M	–	127
2018 Q4	$9.15M	Sell	175,000 -25,000	-13%	-$1.25M	0.17%	88
2018 Q3	$9M	Buy	+200,000	New	+$8.21M	0.11%	114

Other funds holding ALLK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OrbiMed's ALLK Position: Q1 2019 in Review

OrbiMed sold out of Allakos (ALLK) in Q1 2019, closing a stake of 175,000 shares — an estimated $9.15M sold.

OrbiMed first reported a position in ALLK in Q3 2018 and held it in 2 quarters. The position peaked at $9.15M in Q4 2018. 72 funds tracked by Wall St. Rank hold ALLK as of Q1 2019.

OrbiMed reported no remaining Allakos position as of Q1 2019 after selling out during the quarter.
OrbiMed sold 175,000 Allakos shares in Q1 2019, an estimated $9.15M.
OrbiMed first reported a position in Allakos in Q3 2018 and held it in 2 quarters.
OrbiMed's Allakos position peaked at $9.15M in Q4 2018.
72 funds tracked by Wall St. Rank held Allakos as of Q1 2019.

Based on OrbiMed's 13F filing for Q1 2019, filed 15 May 2019.